Financial Performance - The company's revenue increased by 8.1% from $40.7 million for the fiscal year ending June 30, 2022, to $44.0 million for the fiscal year ending June 30, 2023[17]. - Gross profit rose by 11.0% from $35.3 million for the fiscal year ending June 30, 2022, to $39.2 million for the fiscal year ending June 30, 2023[17]. - The gross margin improved by 2.3% to 89.1% for the fiscal year ending June 30, 2023, compared to the previous year[17]. - The average order value has increased, contributing to the overall revenue growth[17]. - The company reported a total of $24.36 million in property, plant, and equipment changes for the year ending June 30, 2023, compared to $7.998 million for the previous year[97]. - The company's total borrowings as of June 30, 2023, amounted to $24.0 million, a decrease from $28.5 million as of June 30, 2022[91]. - The company's premium reserve available for distribution to shareholders as of June 30, 2023, was $72.8 million[88]. - The company had restricted bank deposits of $10.9 million as of June 30, 2023, down from $12.8 million the previous year, which serve as collateral for certain bank borrowings[92]. - The company did not recommend the payment of a final dividend for the twelve months ending June 30, 2023[84]. Market Expansion and Strategy - The company is expanding its BioBytes™ technology into the telemedicine consultation market in Taiwan[17]. - A partnership was established with a local partner in Taiwan to ensure reliable healthcare services for citizens traveling abroad[14]. - The company is focusing on integrating data into a digital platform to enhance user experience and remote patient monitoring[13]. - The company aims to strengthen regional leadership and market sensitivity through dedicated business leadership in each service area[24]. - The company is investing in technology products and medical certification services to enhance its offerings[17]. - The company is leveraging strategic alliances and partnerships to extend its market reach and capabilities[18]. - The global telehealth market is projected to grow from $87.8 billion in 2022 to $285.7 billion by 2027, highlighting significant market expansion opportunities[55]. - Despite global economic challenges, the company remains focused on digital transformation in healthcare systems, particularly in vendor and medical credentialing areas[61]. - The company aims to provide innovative and reliable technology solutions to facilitate the digitalization of healthcare services[61]. - The company operates in North America, the UK, Taiwan, and other countries, indicating a broad international presence[58]. Membership and Collaboration - The company had 125,750 paid members as of June 30, 2023, down from 126,615 members a year earlier, indicating a decrease of 0.7%[58]. - The number of medical credentialing members increased by 181.1%, while the number of members in the UK grew by 4.8%[58]. - The company collaborates with 9,812 registered medical facilities, a decrease of 5.5% from the previous year[58]. - The company had 125,750 paying members in the United States as of June 30, 2023, with no single customer contributing more than 1.0% to total revenue, indicating no concentration risk[98]. Technology and Compliance - The company emphasizes the importance of technology and regulatory compliance as core components of its business strategy[59]. - The company faces operational, compliance, and legal risks associated with its SEC3URE platform, which is critical for revenue generation[74]. - The company has maintained compliance with all relevant laws and regulations across jurisdictions, including the US, Canada, and the UK, during the fiscal year ending June 30, 2023[78]. - The company has increased spending on technology to improve processes and safety for healthcare professionals combating COVID-19[76]. Shareholder and Executive Compensation - The company has granted a total of 5,000,000 share options under the pre-IPO share option plan, representing approximately 1.10% of the total issued shares as of the report date[120]. - As of June 30, 2023, the company has a total of 200 participants in the restricted share award plan, with a maximum of 34,283,411 shares available for purchase, equivalent to 7.5% of the total issued share capital at the time of adoption[124][126]. - The highest remuneration individuals in the company, two of whom are directors, did not receive any shares under the restricted share award plan as of June 30, 2023[126]. - The fair value of the shares granted under the restricted share award plan was HKD 5.50 per share at the time of grant[128]. - The exercise price for the share options granted to Mr. Sheehan is set at USD 0.875 per share[149]. - The share options granted to Mr. Sheehan will vest in five equal installments of 20% each, starting from February 1, 2020, and ending on February 1, 2024[149]. - The weighted average closing price of shares prior to the vesting date of the share awards was HKD 4.66[132]. - The total number of shares awarded during the period was 2,153,698, with 2,365,124 shares vested and 1,290,473 shares exercised[154]. - The company aims to attract suitable talent and retain key personnel through the restricted share award plans, which are valid for 10 years from their respective approval dates[150]. - The company has revised the rules of the restricted share award plans to redistribute the maximum share purchase limit, effective from June 7, 2022[150]. Financial Management - The total amount raised from the IPO was approximately $50.91 million, with $29.83 million utilized as of April 30, 2022[67]. - The company allocated approximately $2.50 million for potential mergers, acquisitions, and strategic alliances, expected to be fully utilized within 24 months from the announcement date[67]. - The company aims to utilize the remaining unallocated funds of approximately $6.62 million based on management's assessment and market conditions[67]. - The company reported an increase in technology investments, with approximately $8.60 million planned for this purpose[67].
中智全球(06819) - 2023 - 年度财报